Skip to main content
MedPathMedPath Home
Clinical Trials/ITMCTR1900002444
ITMCTR1900002444
Recruiting
未知

Clinical study on the clinical efficacy and immune function of anticancer prescription combined with chemotherapy in patients with bladder cancer: A study protocol for a randomized controlled trial

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine0 sitesTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
Male

Investigators

Sponsor
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Eligibility Criteria

Inclusion Criteria

  • •1 In line with transurethral resection of bladder tumor (TURPBT), and pathological diagnosis of malignant tumors;
  • •2 The Karnofsky Performance Status (KPS) score is \>60 points, and the expected survival period is \>1 year;
  • •3 Aged 25 to 80 years;
  • •4 Syndrome differentiation belongs to the syndrome type of qi and blood deficiency and phlegm poisoning internal knot in traditional Chinese medicine;
  • •5 Those who have voluntarily signed an informed consent form.

Exclusion Criteria

  • •1 Allergic constitution and those who are allergic to experimental drugs;
  • •2 Patients with renal cancer, bladder tuberculosis, and urinary calculi;
  • •3 Combined with other malignant tumor patients;
  • •4 Patients with blood system diseases, coagulopathy and autoimmune diseases;
  • •5 Combined with severe cardiovascular disease, cerebrovascular disease, hematopoietic system disease, neuropathic patients;
  • •6 Participated in other clinical researchers 3 months before the trial;
  • •For the above 6 exclusion criteria, as long as one of the criteria is met, the exclusion criteria are met and need to be excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical study for evaluating immunological efficacy of Glypican-3 peptide vaccine in patients with advanced Hepatocellular carcinomaHepatocellular Carcinoma (HCC)
JPRN-UMIN000005093Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East20
Completed
Phase 3
Sub lingual immunotherapy of Nasal allergiesPerennial allergic rhinitis.Other allergic rhinitis
IRCT2017042323235N9Vice chancellor for research, Mashhad University of Medical Sciences40
Not yet recruiting
Not Applicable
Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in Childre
ITMCTR1900002294First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Recruiting
Phase 1
evaluate the safety and immunomodulatory efficacy of Byolic CC supplementImmunomodulatory effect on healthy volunteers.
IRCT20240304061158N4Behpad Teb Iranian90
Active, not recruiting
Phase 1
A study to investigate the clinical and immunological effects on field cancerization in patients treated with PD-1 inhibition for advanced or metastatic cutaneous squamous cell carcinomaadvanced or metastatic cutaneous squamous cell carcinomaMedDRA version: 24.1Level: LLTClassification code 10085908Term: Cutaneous squamous cell carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-006372-17-DEMuehlenkreiskliniken AoeR20